🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Does Urinary TIMP2 and IGFBP7 Can Identify High Risk Patients of Progression From Mild and Moderate to Severe Acute Kidney Injury During Septic Shock?

Recruitingn/aAges 18 Years - anyAllCentre Hospitalier Universitaire, Amiens
NCT03547414 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

Septic shock is one of the leading causes of death in patients admitted to the intensive care unit (ICU). Acute kidney injury (AKI) occurs in almost 50% of septic patients and is associated with significant mortality. Progression to the last stage (KDIGO stage 3) of AKI is an important step in the disease, as it usually requires initiation of RRT. Renal biomarkers are unable to accurately identify those patients who will progress to severe AKI (KDIGO 3). However, identification of patients at risk of progression to severe AKI could help the clinician to initiate optimal therapy including RRT. A new urine test, the Nephrocheck™ corresponding to the product of the urinary concentrations of 2 markers of renal tubule injury (TIMP2 and IGFBP7) has been validated. The Investigator have already performed two previous studies including septic shock patients (AKICHECK and BIOOCHECK). those previo

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: * Age 18 or over * Septic shock (according to Bone's criteria) within 4 hours of introduction of catecholamines * AKI, characterized by a KDIGO score ≥ 1 * Social security coverage Exclusion Criteria: * AKI requiring emergency RRT (in the critical care physician's opinion). * Anuria * Stage 4-5 chronic kidney failure with a GFR below 30 ml/min. * Rapidly progressing renal disorders (glomerulonephritis, HUS, blockage, etc.) * Obstructive AKI * Probable glomerular damage (nephritic syndrome, nephrotic syndrome, chronic glomerulonephritis) * Pregnancy or breastfeeding * Legal guardianship or lack of social security coverage. * Cardiocirculatory arrest * Life expectancy \<48 hours. * Child C cirrhosis * Prior occurrence of AKI during the current hospital stay * Transplantation * Subject participating in another study with an exclusion period ongoing at the time of the pre-inclusion
💊

What it tests

  • Nephrocheck test
📍

Where

1 site
CHU Amiens-Picardie
Amiens, France
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy